These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1729 related items for PubMed ID: 24418304

  • 21. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
    Mousseaux C, Joly BS, Mohamadou I, Arrestier R, Hertig A, Rafat C.
    BMC Nephrol; 2020 May 29; 21(1):204. PubMed ID: 32471388
    [Abstract] [Full Text] [Related]

  • 22. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.
    Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B.
    Semin Hematol; 2004 Jan 29; 41(1):75-82. PubMed ID: 14727262
    [Abstract] [Full Text] [Related]

  • 23. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.
    Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Häberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, Obser T, Santer R, Sykora KW.
    Blood; 2003 Mar 01; 101(5):1845-50. PubMed ID: 12393505
    [Abstract] [Full Text] [Related]

  • 24. Molecular mechanisms in thrombotic thrombocytopenic purpura.
    Tsai HM.
    Semin Thromb Hemost; 2004 Oct 01; 30(5):549-57. PubMed ID: 15497097
    [Abstract] [Full Text] [Related]

  • 25. [Treatment strategy for patients with thrombotic thrombocytopenic purpura].
    Yagi H.
    Rinsho Ketsueki; 2021 Oct 01; 62(8):1222-1228. PubMed ID: 34497210
    [Abstract] [Full Text] [Related]

  • 26. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
    Saha M, McDaniel JK, Zheng XL.
    J Thromb Haemost; 2017 Oct 01; 15(10):1889-1900. PubMed ID: 28662310
    [Abstract] [Full Text] [Related]

  • 27. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B.
    N Engl J Med; 1998 Nov 26; 339(22):1578-84. PubMed ID: 9828245
    [Abstract] [Full Text] [Related]

  • 28. Atypical presentations of thrombotic thrombocytopenic purpura: a review.
    Sarode R.
    J Clin Apher; 2009 Nov 26; 24(1):47-52. PubMed ID: 19073011
    [Abstract] [Full Text] [Related]

  • 29. [The frontline of TMA management].
    Saito K, Matsumoto M.
    Rinsho Ketsueki; 2022 Nov 26; 63(5):463-470. PubMed ID: 35662172
    [Abstract] [Full Text] [Related]

  • 30. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K.
    Arterioscler Thromb Vasc Biol; 2015 Nov 26; 35(11):2336-42. PubMed ID: 26338302
    [Abstract] [Full Text] [Related]

  • 31. Thrombotic thrombocytopenic purpura.
    Lämmle B, Kremer Hovinga JA, Alberio L.
    J Thromb Haemost; 2005 Aug 26; 3(8):1663-75. PubMed ID: 16102032
    [Abstract] [Full Text] [Related]

  • 32. [Diagnosis and management of thrombotic microangiopathies].
    Matsumoto M.
    Rinsho Ketsueki; 2015 Oct 26; 56(10):2092-9. PubMed ID: 26458449
    [Abstract] [Full Text] [Related]

  • 33. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM, Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.
    Blood; 2002 Aug 01; 100(3):778-85. PubMed ID: 12130486
    [Abstract] [Full Text] [Related]

  • 34. [Diagnosis of thrombotic thrombocytopenic purpura].
    Galstyan GM, Klebanova EE.
    Ter Arkh; 2020 Dec 15; 92(12):207-217. PubMed ID: 33720596
    [Abstract] [Full Text] [Related]

  • 35. Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.
    Nakayama S, Hirashio S, Yorishima H, Doi T, Yoshida Y, Matsumoto M, Masaki T.
    CEN Case Rep; 2019 Nov 15; 8(4):266-270. PubMed ID: 31177384
    [Abstract] [Full Text] [Related]

  • 36. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
    Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G.
    Am J Kidney Dis; 2015 Dec 15; 66(6):1067-70. PubMed ID: 26409664
    [Abstract] [Full Text] [Related]

  • 37. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
    Matsumoto M.
    Rinsho Ketsueki; 2021 Dec 15; 62(5):480-485. PubMed ID: 34248125
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.
    Manea M, Karpman D.
    Pediatr Nephrol; 2009 Mar 15; 24(3):447-58. PubMed ID: 18807073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 87.